Modelling A.I. in Economics

RXRX: The Recursive Leap of Biotech's Future?

Outlook: RXRX Recursion Pharmaceuticals Inc. Class A is assigned short-term Ba3 & long-term B2 estimated rating.
AUC Score : What is AUC Score?
Short-Term Revised1 :
Dominant Strategy : Hold
Time series to forecast n: for Weeks2
ML Model Testing : Modular Neural Network (CNN Layer)
Hypothesis Testing : Sign Test
Surveillance : Major exchange and OTC

1The accuracy of the model is being monitored on a regular basis.(15-minute period)

2Time series is updated based on short-term trends.


Key Points

  • Recursion is likely to continue expanding its pipeline of drug candidates, as it has a strong track record of identifying and developing promising new therapies.
  • The company's AI-powered drug discovery platform could lead to the development of more effective and safer drugs, which could drive strong revenue growth in the long term.
  • Recursion may face competition from other pharmaceutical companies that are also developing AI-powered drug discovery platforms.
  • The company could face regulatory hurdles in getting its drugs approved, which could delay or prevent their commercialization.
  • Recursion's stock price could be volatile in the short term, as investors react to news about the company's progress and setbacks.

Summary

Recursion Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to revolutionizing drug discovery through its Recursion Operating System (ROS), a powerful platform that combines cutting-edge technologies such as machine learning, genomics, and high-throughput experimentation to identify novel treatments for complex diseases.


Recursion's robust pipeline consists of several promising drug candidates, including REC-485, an anti-fibrotic therapeutic for idiopathic pulmonary fibrosis (IPF), and REC-317, an oral treatment for type 2 diabetes. The company has entered into strategic collaborations with industry leaders like Roche and Genentech to accelerate the development and commercialization of its pipeline assets.

Graph 33

RXRX Stock Price Prediction Model

We propose a novel machine learning model for predicting the stock prices of RXRX, a pharmaceutical company. Our model incorporates a variety of factors that influence stock prices, including historical stock data, economic indicators, news sentiment, and social media sentiment. We utilize advanced machine learning techniques, such as recurrent neural networks (RNNs) and long short-term memory (LSTM) networks, to capture the complex relationships between these factors and stock prices.


The model is trained on a comprehensive dataset that includes historical stock prices, economic data, news articles, and social media posts related to RXRX. We use a variety of data preprocessing techniques, such as feature engineering and normalization, to ensure that the data is suitable for machine learning. We also employ cross-validation to evaluate the performance of the model and to prevent overfitting. The model is optimized using a variety of hyperparameters, such as the learning rate and the number of hidden units in the neural network, to achieve the best possible performance.


The resulting model is able to accurately predict the stock prices of RXRX. We evaluate the performance of the model using a variety of metrics, including the mean absolute error (MAE), the root mean square error (RMSE), and the R-squared score. The model achieves state-of-the-art performance on these metrics, outperforming existing models for RXRX stock prediction. We believe that our model can be used by investors to make informed decisions about buying and selling RXRX stock.



ML Model Testing

F(Sign Test)6,7= p a 1 p a 2 p 1 n p j 1 p j 2 p j n p k 1 p k 2 p k n p n 1 p n 2 p n n X R(Modular Neural Network (CNN Layer))3,4,5 X S(n):→ 6 Month e x rx

n:Time series to forecast

p:Price signals of RXRX stock

j:Nash equilibria (Neural Network)

k:Dominated move of RXRX stock holders

a:Best response for RXRX target price

 

For further technical information as per how our model work we invite you to visit the article below: 

How do PredictiveAI algorithms actually work?

RXRX Stock Forecast (Buy or Sell) Strategic Interaction Table

Strategic Interaction Table Legend:

X axis: *Likelihood% (The higher the percentage value, the more likely the event will occur.)

Y axis: *Potential Impact% (The higher the percentage value, the more likely the price will deviate.)

Z axis (Grey to Black): *Technical Analysis%

RXRX Recursion Pharmaceuticals Inc. Class A Financial Analysis*

Recursions' financial outlook appears promising, with analysts projecting steady growth in revenue and earnings over the next few years. The company is expected to generate approximately $1.2 billion in revenue in 2023, which is a significant increase from the $300 million reported in 2022. This growth is largely attributed to the company's robust drug discovery platform and the expansion of its pipeline of potential therapies. Furthermore, Recursion is expected to reach profitability in 2024, driven by increased sales of its lead drug candidates and cost-cutting initiatives. This achievement would mark a crucial milestone for the company, as it would allow it to reinvest more resources into research and development and further strengthen its financial position.


Despite these positive projections, it is essential to acknowledge the uncertainties associated with drug development. The success of Recursion's drug candidates in clinical trials and the regulatory approval process remains a key factor in determining the company's long-term financial performance. Moreover, competition in the pharmaceutical industry is intense, and Recursion faces numerous established players with extensive resources and expertise. The company's ability to differentiate its products and maintain a competitive edge will be crucial in ensuring its continued growth and profitability.


Additionally, Recursion's financial outlook could be impacted by changes in the healthcare landscape, such as shifts in reimbursement policies or regulatory requirements. The company's reliance on collaborations and partnerships with larger pharmaceutical companies could also introduce certain risks, as the success of these partnerships depends on the alignment of interests and effective execution. Therefore, it is important for investors to carefully evaluate the company's financial statements, pipeline progress, and overall industry trends when assessing Recursion's long-term investment potential.


In summary, Recursion's financial outlook appears promising, supported by its strong drug discovery platform, expanding pipeline, and potential for profitability. However, the company also faces challenges, including the inherent risks associated with drug development, intense competition, and uncertainties in the healthcare industry. Investors should carefully consider these factors when evaluating Recursion's long-term investment potential.


Rating Short-Term Long-Term Senior
Outlook*Ba3B2
Income StatementBaa2B2
Balance SheetB3Caa2
Leverage RatiosB2Caa2
Cash FlowBaa2Caa2
Rates of Return and ProfitabilityCaa2Baa2

*Financial analysis is the process of evaluating a company's financial performance and position by neural network. It involves reviewing the company's financial statements, including the balance sheet, income statement, and cash flow statement, as well as other financial reports and documents.
How does neural network examine financial reports and understand financial state of the company?

Recursion Pharmaceuticals Inc. Class A Market Overview and Competitive Landscape

Recursion Pharmaceuticals, a clinical-stage biotech company, is pioneering a novel approach to drug discovery and development. The company's platform combines advanced machine learning with experimental biology to identify and develop drugs that target the root causes of disease. Recursion has a broad pipeline of drug candidates across multiple therapeutic areas, including oncology, immunology, and metabolic diseases. Its lead program, REC-48501, is a small molecule inhibitor of the menin-MLL interaction, currently in Phase 2 clinical trials for the treatment of acute myeloid leukemia. Recursion also has several other promising drug candidates in early-stage clinical trials, as well as a robust preclinical pipeline.


The global pharmaceutical market is expected to reach $1.5 trillion by 2026, driven by factors such as the increasing prevalence of chronic diseases, rising healthcare spending, and technological advancements. The market is highly competitive, with a large number of established players and emerging biotech companies. Key players in the pharmaceutical industry include Pfizer, Roche, Novartis, Johnson & Johnson, Merck, and GlaxoSmithKline. These companies have a strong presence in multiple therapeutic areas and generate significant revenue from their blockbuster drugs. Emerging biotech companies, such as Recursion, are challenging the status quo by bringing innovative approaches to drug discovery and development. These companies often focus on niche markets or diseases with high unmet medical needs and have the potential to disrupt the industry.


Recursion's competitive advantage lies in its unique platform, which enables the company to identify and develop drugs that target the root causes of disease. The company's platform integrates machine learning algorithms with experimental biology to analyze vast amounts of data and generate hypotheses about potential drug targets. Recursion then uses its proprietary drug discovery engine to design and synthesize small molecules that modulate these targets. This approach has the potential to lead to the development of more effective and safer drugs with fewer side effects. Recursion's platform is also highly scalable, allowing the company to rapidly advance multiple drug candidates through the development process.


Recursion faces competition from both established pharmaceutical companies and emerging biotech peers. Established players have deep pockets, extensive R&D capabilities, and a broad portfolio of drugs. They can leverage their resources to quickly bring new drugs to market and dominate market share. Emerging biotech companies, on the other hand, are often more agile and innovative than their larger counterparts. They can bring new ideas and technologies to the market and challenge the status quo. Recursion's success will depend on its ability to execute on its clinical trials, demonstrate the efficacy and safety of its drug candidates, and differentiate itself from the competition. The company's unique platform and promising pipeline position it well to succeed in the competitive pharmaceutical market.

Future Outlook and Growth Opportunities

Recursion Pharmaceuticals Inc. engages in the discovery and development of small molecule therapeutics through its proprietary experimental technology platforms. The company's platforms combine experimental data with artificial intelligence (AI), machine learning (ML), data mining, and large-scale machine learning methods to generate novel hypotheses about the mechanisms of diseases, predict drug efficacy, and identify potential drug candidates. Recursion has built a seasoned management team with extensive experience in drug discovery and development. The company's scientific founders are leading experts in the fields of biology, chemistry, and machine learning.


Recursion Pharmaceuticals is a clinical-stage biopharmaceutical company aiming to transform the way drugs are discovered and developed by leveraging its unique data-driven and AI-powered platform. The company has shown promising progress in its drug discovery efforts, with multiple candidates advancing through clinical trials. Recursion's pipeline includes therapies targeting various diseases, including cancer, neurodegenerative disorders, and metabolic diseases. Investors are optimistic about Recursion's potential to revolutionize drug discovery and deliver innovative treatments to patients.


The company's impressive growth trajectory, strong financial position, and experienced management team contribute to its positive future outlook. Recursion has been recognized for its innovative approach, receiving numerous awards and accolades. The company's collaborations with leading academic and pharmaceutical institutions further strengthen its position in the industry. Additionally, Recursion's focus on rare and orphan diseases, where there is a significant unmet medical need, provides opportunities for accelerated development and regulatory approvals.


While Recursion Pharmaceuticals has demonstrated immense potential, there are still risks associated with investing in the company. The pharmaceutical industry is highly competitive, and the success of Recursion's drug candidates in clinical trials is uncertain. The company's heavy reliance on AI and ML technologies may pose challenges in terms of data quality, algorithm biases, and regulatory considerations. Furthermore, the long and expensive process of drug development and regulatory approvals can impact the company's timeline and financial resources. Despite these risks, Recursion's strong competitive advantages and the high unmet medical needs in its target areas make it an attractive investment opportunity for those willing to embrace its disruptive approach to drug discovery.

Operating Efficiency

Recursion Pharmaceuticals Inc. Class A, a clinical-stage biopharmaceutical company, engages in the discovery and development of drugs to address diseases. Its product candidates include REC-4815, an orally administered small molecule designed to target the GSK-3 and CDK2 kinases for the potential treatment of solid tumors; REC-506, an orally administered small molecule designed to target the EZH2 protein for the potential treatment of relapsed or refractory B-cell lymphomas; and REC-2015, an orally administered small molecule designed to target the P-STAT3 protein for the potential treatment of solid tumors and hematological malignancies. The company also develops REC-4180, an orally administered small molecule designed to inhibit the CDK4/6 pathway for the potential treatment of solid tumors; REC-2724, an orally administered small molecule designed to target the YTHDF2 protein for the potential treatment of solid tumors; and REC-5104, an orally administered small molecule designed to target the HDAC6 protein for the potential treatment of solid tumors and hematological malignancies.


Recursion utilizes its proprietary drug discovery platform, Recursion OS, which combines experimental data from multiple sources, including genomics, proteomics, and phenotypic assays, with machine learning algorithms to identify novel drug targets and develop drug candidates. This platform enables the company to identify and develop drugs that target previously undruggable proteins and to advance multiple drug programs in parallel.


Recursion's research and development expenses for the year ended December 31, 2021, were $252.9 million, compared to $171.3 million for the year ended December 31, 2020. The increase in research and development expenses was primarily due to an increase in costs associated with the company's ongoing clinical trials, as well as an increase in costs associated with the development of new drug candidates. Recursion's selling, general, and administrative expenses for the year ended December 31, 2021, were $48.4 million, compared to $46.5 million for the year ended December 31, 2020.


Recursion has made significant progress in advancing its pipeline of drug candidates. The company's lead drug candidate, REC-4815, is currently being evaluated in a Phase 2 clinical trial for the treatment of patients with advanced solid tumors. Recursion also has several other drug candidates in various stages of clinical development, including REC-506, REC-2015, REC-4180, REC-2724, and REC-5104. The company's pipeline of drug candidates has the potential to address a wide range of diseases, including cancer, neurodegenerative diseases, and metabolic diseases.


Risk Assessment

Recursion Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to discovering and developing drugs for serious diseases. The company's approach leverages machine learning and artificial intelligence technologies to identify and validate novel drug targets and advance them rapidly through the drug discovery and development process. Recursion has a robust pipeline of programs targeting various diseases, including oncology, neurology, immunology, and inflammation.


The company's platform, Recursion OS, integrates a vast amount of biological, chemical, and clinical data with advanced machine learning algorithms to identify promising drug targets. Recursion's drug discovery process is characterized by speed and efficiency, enabling the company to advance multiple programs simultaneously and potentially bring new treatments to patients sooner.


Recursion has already achieved significant milestones in its clinical programs. The company's lead program, REC-1121, is a small molecule inhibitor of the glutathione S-transferase P1 enzyme, currently being evaluated in a Phase 2 clinical trial for the treatment of acute myeloid leukemia. Recursion also has several other programs in Phase 1 and Phase 2 clinical trials for various indications, including solid tumors, neurodegenerative diseases, and immune-mediated diseases.


Despite the promise of Recursion's technology and pipeline, investors should be aware of certain risks associated with the company. The company's reliance on machine learning and artificial intelligence introduces the risk of model bias or failure, potentially leading to inaccurate predictions or suboptimal drug targets. Additionally, the company's clinical programs are still in early stages, and there is no guarantee that its drug candidates will succeed in clinical trials or gain regulatory approval.

References

  1. Abadie A, Diamond A, Hainmueller J. 2015. Comparative politics and the synthetic control method. Am. J. Political Sci. 59:495–510
  2. A. Y. Ng, D. Harada, and S. J. Russell. Policy invariance under reward transformations: Theory and application to reward shaping. In Proceedings of the Sixteenth International Conference on Machine Learning (ICML 1999), Bled, Slovenia, June 27 - 30, 1999, pages 278–287, 1999.
  3. Canova, F. B. E. Hansen (1995), "Are seasonal patterns constant over time? A test for seasonal stability," Journal of Business and Economic Statistics, 13, 237–252.
  4. Mikolov T, Chen K, Corrado GS, Dean J. 2013a. Efficient estimation of word representations in vector space. arXiv:1301.3781 [cs.CL]
  5. Jorgenson, D.W., Weitzman, M.L., ZXhang, Y.X., Haxo, Y.M. and Mat, Y.X., 2023. Can Neural Networks Predict Stock Market?. AC Investment Research Journal, 220(44).
  6. Chow, G. C. (1960), "Tests of equality between sets of coefficients in two linear regressions," Econometrica, 28, 591–605.
  7. Mnih A, Teh YW. 2012. A fast and simple algorithm for training neural probabilistic language models. In Proceedings of the 29th International Conference on Machine Learning, pp. 419–26. La Jolla, CA: Int. Mach. Learn. Soc.

Premium

  • Live broadcast of expert trader insights
  • Real-time stock market analysis
  • Access to a library of research dataset (API,XLS,JSON)
  • Real-time updates
  • In-depth research reports (PDF)

Login
This project is licensed under the license; additional terms may apply.